Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 4
2001 4
2002 6
2003 1
2004 1
2005 4
2006 2
2007 4
2008 5
2009 3
2010 6
2011 15
2012 18
2013 14
2014 11
2015 8
2016 2
2017 4
2018 5
2019 4
2020 5
2021 4
2022 4
2023 4
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. O'Malley DM, et al. Among authors: krivak tc. Target Oncol. 2023 Jul;18(4):471-503. doi: 10.1007/s11523-023-00970-w. Epub 2023 Jun 3. Target Oncol. 2023. PMID: 37268756 Free PMC article. Review.
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Abkevich V, et al. Among authors: krivak t. Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9. Br J Cancer. 2012. PMID: 23047548 Free PMC article.
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. Hardesty MM, et al. Among authors: krivak tc. Gynecol Oncol. 2022 Aug;166(2):219-229. doi: 10.1016/j.ygyno.2022.05.020. Epub 2022 Jun 9. Gynecol Oncol. 2022. PMID: 35690498 Free article. Clinical Trial.
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Arend RC, Monk BJ, Shapira-Frommer R, Haggerty AF, Alvarez EA, Amit A, Alvarez Secord A, Muller C, Casado Herraez A, Herzog TJ, Tewari KS, Cohen JG, Huang M, Yachnin A, Holeman LL, Ledermann JA, Rachmilewitz Minei T, Buyse M, Fain Shmueli S, Lavi M, Harats D, Penson RT; OVAL/GOG-3018 Investigators. Arend RC, et al. J Clin Oncol. 2024 Jan 10;42(2):170-179. doi: 10.1200/JCO.22.02915. Epub 2023 Oct 31. J Clin Oncol. 2024. PMID: 37906726 Clinical Trial.
Stump the professor.
Gonzalez DI Jr, Gobern J, Krivak T, Gordon M. Gonzalez DI Jr, et al. Among authors: krivak t. Obstet Gynecol Surv. 2000 Apr;55(4):193-4. doi: 10.1097/00006254-200004000-00001. Obstet Gynecol Surv. 2000. PMID: 10758618 No abstract available.
121 results